Efficacy of Sorafenib in the Management of Non-Small Cell Lung Cancer: A Systematic Review

Main Article Content

Rebaz M. Ali
Sami S. Omar
Fahmi H. Kakamad
Diyar A. Omar
Yousif M. Mahmood
Mohammed Q. Mustafa
Aland S. Abdullah
Marwan N. Hassan
Hiwa O. Abdullah
Hawbash M. Rahim
Rawezh Q. Salih
Berun A. Abdalla

Keywords

Lung cancer, Sorafenib, Erlotinib, Targeted molecular therapy, Tyrosine-kinase inhibitor

Abstract

Introduction


The current standard treatment approach for non-small cell lung cancer (NSCLC) is surgery. Recently, targeted therapy has emerged as a promising new treatment option. In this systematic review, the efficacy of sorafenib, when given alone or combined with erlotinib, in managing NSCLC is reviewed.


Methods


To identify English language studies published up to March 8th, 2024, the Google Scholar, CINAHL, PubMed/MEDLINE, Cochrane Library, Web of Science, and EMBASE databases were screened, and the data were assessed.


Results


The systematic search revealed 208 papers; however, only 10 were eligible to be included. The sample size was 1080 patients, of which 848 were in the sorafenib group, and 232 were in the sorafenib with erlotinib combination group. In the sorafenib group, the partial response was 2.4%, stable disease was reported in 25%, and 56 cases (6.6%) had progressive disease. In the combination group, partial response, stable disease, and progressive disease were 16.8%, 48.3%, and 19.8%, respectively. In the combination group, the median overall survival was 231 days, and the progression-free survival (PFS) was 141 days. However, in the sorafenib group, the median overall survival was 180 days, and the PFS was 82 days. Fatigue was the most common adverse event, reported in 325 (30.1%) patients. Among them, 235 cases (27.7%) were in the sorafenib group, and 90 cases (38.8%) were in the combination group.


Conclusion


Combination therapy may result in better overall survival and PFS than sorafenib alone, with slightly similar adverse events.

Abstract 36 | PDF Downloads 6

References

1. Clark SB, Alsubait S. Non–Small Cell Lung Cancer. 2023 Sep 4. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan. PMID: 32965978. doi:N/A
2. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA: a cancer journal for clinicians. 2020 ;70(3):145-64. doi:10.3322/caac.21601
3. Sher T, Dy GK, Adjei AA. Small cell lung cancer. InMayo Clinic Proceedings 2008 (Vol. 83, pp. 355-367). Elsevier. doi:10.4065/83.3.355
4. Mohemed FM, Fatih BN, Qadir AA, Abdalla SH, Mahmood ZH. Cancer Publications in One Year (2022): A Cross-Sectional Study. Barw Medical Journal. 2023;1(2):18-26. doi:10.58742/bmj.v1i2.30
5. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. Journal of Thoracic Oncology. 2015;10(9):1243-60. doi:10.1097/JTO.0000000000000630
6. Alduais Y, Zhang H, Fan F, Chen J, Chen B. Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. Medicine. 2023 ;102(8):e32899. doi:10.1097/MD.0000000000032899
7. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. InMayo clinic proceedings 2008 (Vol. 83, pp. 584-594). Elsevier. doi:10.4065/83.5.584
8. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB, et al. Staging non—small cell lung cancer by whole-body positron emission tomographic imaging. The Annals of thoracic surgery. 1995 ;60(6):1573-82. doi:10.1016/0003-4975(95)00752-0
9. Bitenc M, Cufer T, Kern I, Miklavcic M, Petrovic S, Groznik V, Sadikov A. Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer. Radiol Oncol. 2022 Aug 14;56(3):346-354. doi:10.2478/raon-2022-0030
10. Muhialdeen AS, Ahmed JO, Baba HO, Abdullah IY, Hassan HA, Najar KA, et al. Kscien’s list; a new strategy to discourage predatory journals and publishers (second version). Barw Medical Journal. 2023;1(1):24-26. doi:10.58742/bmj.v1i1.14
11. Paz-Ares L, Hirsh V, Zhang L, De Marinis F, Yang JC, Wakelee HA, et al. Monotherapy Administration of Sorafenib in patients with non–small cell lung cancer (MISSION) trial: a phase III, multicenter, placebo-controlled trial of Sorafenib in patients with relapsed or refractory predominantly nonsquamous non–small-cell lung cancer after 2 or 3 previous treatment regimens. Journal of thoracic oncology. 2015 ;10(12):1745-53. doi:10.1097/JTO.0000000000000693
12. Blumenschein Jr GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non–small-cell lung cancer. Journal of Clinical Oncology. 2009 ;27(26):4274-80. doi:10.1200/JCO.2009.22.0541
13. Dingemans AM, Mellema WW, Groen HJ, van Wijk A, Burgers SA, Kunst PW, et al. A Phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non–small cell lung cancer with a KRAS mutation. Clinical Cancer Research. 2013 ;19(3):743-51. doi:10.1158/1078-0432.CCR-12-1779
14. Kelly RJ, Rajan A, Force J, Lopez-Chavez A, Keen C, Cao L, et al. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non–small-cell lung cancer receiving sorafenib. Clinical cancer research. 2011 ;17(5):1190-9. doi:10.1158/1078-0432.CCR-10-2331
15. Wakelee HA, Lee JW, Hanna NH, Traynor AM, Carbone DP, Schiller JH. A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43–9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern Cooperative Oncology Group Study E2501. Journal of Thoracic Oncology. 2012 ;7(10):1574-82. doi:10.1097/JTO.0b013e31826149ba


16. Spigel DR, Rubin MS, Gian VG, Shipley DL, Burris III HA, Kosloff RA, et al. Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). Lung Cancer. 2017; 113:79-84. doi:10.1016/j.lungcan.2017.09.007
17. Dy GK, Hillman SL, Rowland Jr KM, Molina JR, Steen PD, Wender DB, et al. A front‐line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer. 2010 ;116(24):5686-93. doi:10.1002/cncr.25448
18. Spigel DR, Burris III HA, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non–small-cell lung cancer. Journal of clinical oncology. 2011 ;29(18):2582-9. doi:10.1200/JCO.2010.30.7678
19. Lind JS, Dingemans AM, Groen HJ, Thunnissen FB, Bekers O, Heideman DA, et al. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non–small cell lung cancer. Clinical Cancer Research. 2010 ;16(11):3078-87. doi:10.1158/1078-0432.CCR-09-3033
20. Lim SM, Cho BC, Kim SW, Kang SY, Heo DS, Kim HT, et al. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). Lung cancer. 2016 ;93:1-8. doi:10.1016/j.lungcan.2015.12.005
21. Faraz Siddiqui, Siddiqui AH. Lung Cancer [Internet]. Nih.gov. StatPearls Publishing; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482357/
22. Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemporary Oncology/Współczesna Onkologia. 2021 ;25(1):45-52. doi:10.5114/wo.2021.103829
23. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003 ;123(1):21S-49S. doi:10.1378/chest.123.1_suppl.21s
24. Ruano-Ravina A, Provencio M, de Juan VC, Carcereny E, Estival A, Rodríguez-Abreu D, et al. Are there differences by sex in lung cancer characteristics at diagnosis? —a nationwide study. Translational Lung Cancer Research. 2021 ;10(10):3902. doi:10.21037/tlcr-21-559
25. Xing PY, Zhu YX, Wang L, Hui ZG, Liu SM, Ren JS, et al. What are the clinical symptoms and physical signs for non‐small cell lung cancer before diagnosis is made? A nation‐wide multicenter 10‐year retrospective study in China. Cancer medicine. 2019 ;8(8):4055-69. doi:10.1002/cam4.2256
26. ECOG-ACRIN Cancer Research Group. ECOG Performance Status Scale. ECOG-ACRIN Cancer Research Group. 2022. Available from: https://ecog-acrin.org/resources/ecog-performance-status/
27. Sehgal K, Gill RR, Widick P, Bindal P, McDonald DC, Shea M, et al. Association of performance status with survival in patients with advanced non–small cell lung cancer treated with pembrolizumab monotherapy. JAMA network open. 2021 ;4(2):e2037120-. doi:10.1001/jamanetworkopen.2020.37120
28. Guo Q, Liu L, Chen Z, Fan Y, Zhou Y, Yuan Z, et al. Current treatments for non-small cell lung cancer. Frontiers in oncology. 2022;12:945102. doi:10.3389/fonc.2022.945102
29. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. The oncologist. 2008 ;13(S1):5-13. doi:10.1634/theoncologist.13-S1-5
30. Cheng Y, Zhang T, Xu Q. Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm. 2021 ;2(4):692-729. doi:10.1002/mco2.105
31. Ali RM, Kakamad FH, Abdullah HO, Abdulla SH, Ahmed SF, Amin BJ, et al. Pembrolizumab (Anti-PD-1) Immunotherapy in Malignant Pleural Mesothelioma: A Systematic Review of the Current Literature. Barw Medical Journal. 2023;1(3):6-13. doi:10.58742/bmj.v1i2.34
32. Sami S. Omar, Rebaz Haji Ali, Shalaw H. Abdalla, Dlsoz M. Hussein, Belan Mikaeil M.Radha, Alaa B.Latif,et al. Role of Durvalumab (Anti-PD-1) in the Management of Mesothelioma: ASystematic Review of the Current Literature. Barw Medical Journal 2023;1(4):32-39. doi:10.58742/peq00z60
33. Metro G, Minotti V, Crinò L. Years of sorafenib investigation in advanced non-small cell lung cancer: is there a ‘NExUS’linking an unsuccessful treatment and a potentially active one?. Journal of Thoracic Disease. 2012 ;4(6):635. doi:10.3978/j.issn.2072-1439.2012.10.06
34. Zhang J, Gold KA, Kim E. Sorafenib in non-small cell lung cancer. Expert opinion on investigational drugs. 2012 ;21(9):1417-26. doi:10.1517/13543784.2012.699039
35. Li Y, Gao ZH, Qu XJ. The adverse effects of sorafenib in patients with advanced cancers. Basic & Clinical Pharmacology & Toxicology. 2015 ;116(3):216-21. doi:10.1111/bcpt.12365

Effect of Sunitinib in the Management of Lung Cancer: A Systematic Review of Clinical Trials

Rebaz M. Ali, Sami S. Omar, Fahmi H. kakamad, Harem K. Ahmed, Diyar A. Omar, Yousif M. Mahmood,...